Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA new Locations section appears with Connecticut listed, replacing the older Connecticut Locations header; the HHS Vulnerability Disclosure footer link and the older revision label were removed.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.3.2 added and Revision: v3.2.0 removed; this is a minor metadata update with no changes to study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe site-wide notification about government funding and NIH operation status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange Detected- The update seems limited to dates and minor formatting; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check91 days agoChange DetectedThe page now includes a government-operating-status notice and a v3.2.0 revision, replacing the prior v3.1.0 revision.SummaryDifference2%

- Check98 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.